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Isoﬂavone intake through foods and dietary supplements has both health advocates and critics. The latter come from a concern
about the estrogenic eﬀects of isoﬂavones in certain species. However, careful removal of isoﬂavones and other estrogens from
the diet of rodents leads to the metabolic syndrome. These results suggest that isoﬂavones have other mechanisms of action,
potentially those involving regulation of fatty acid metabolism via the nuclear receptors PPARα and PPARγ.T h eg o a lo ft h i s
paper was to examine the evidence for isoﬂavone/PPAR signaling and to identify diseases in which such signaling would have an
important impact. It is therefore of note that investigators using a chemical structure approach to discover PPAR ligands identiﬁed
isoﬂavones as the best structures in the library of compounds that they tested. Future studies will involve careful identiﬁcation of
the underlying mechanisms whereby isoﬂavones have their action via PPAR signaling.
1.Introduction
The importance of plant estrogens (phytoestrogens) in the
human diet has become a topic of great interest [1], as well
as dispute [2]. The principal phytoestrogens in the American
and Western European diets are the isoﬂavones in soy foods
[3, 4]. It is noteworthy that soy protein is widely used for
animal diets both in commercial food production and for
animals in research studies. In the latter, it has been realized
byseveralinvestigatorsthatisoﬂavoneshavesigniﬁcant phys-
iological eﬀects. Many toxicologists have been concerned
that the estrogenic properties of isoﬂavones could lead to
infertility [5]. Such a connection was ﬁrst observed in sheep
infertility in Western Australia which was attributed to the
red clover (Trifolium pratense) that theyconsume. Red clover
contains large amounts of isoﬂavones [6]. Similar infertility
eﬀects were observed in captive cheetahs [7], although this
mayberelatedtothefailureofthecatfamilytoglucuronidate
many xenobiotics [8]. On the other hand, removal of soy
from the diets of rats in chemoprevention experiments led
to an increase in incidence of chemically induced mammary
tumors [9]. Similarly, soy improved the blood pressure of
spontaneously hypertensive rats on a high-salt diet [10]a n d
ameliorated the cold sensitivity of mice with gene knockouts
of the ﬁrst members of the β oxidation of long-chain fatty
acids [11]. Many such examples of the disparate eﬀects of
isoﬂavones have been reported which stem, in part, from a
lack of understanding of biological mechanisms of action of
isoﬂavones in individual species.
In this paper, we discuss several lines of emerging
evidence implicating isoﬂavones as activators of PPARα and
PPARγ. Indeed, we hypothesize that isoﬂavone-dependent
activation of PPARα and PPARγ signaling is key to under-
standing how these compounds aﬀect multiple pathophysio-
logical processes. Intriguingly, a study employing structure-
based virtual screening with induced ﬁt locking analysis
for identifying novel PPARγ ligands revealed that out
of a natural product library comprising 200 compounds2 PPAR Research
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Figure 1: The isoﬂavones: generic 7-hydroxy-benzopyran-4-one
ligands for PPARγ. Isoﬂavones have a B-ring aryl substituent in
the 3-position and a Δ2−3double bond. Common isoﬂavones are
daidzein (R5 = R6 = R8 = H, R7 = R
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4 = OCH3). The chemical library search also showed that the
atom at position-3 in the B-ring can be either carbon or nitrogen.
isoﬂavones were the optimal PPARγ ligands [12]. We have
shown that modiﬁcation of isoﬂavones by nitration and/or
chlorination, which may occur in vivo, forms novel products
withaltered eﬃcacyforPPARγ activation[13, 14]. Addition-
ally, a recent comprehensive structure-activity relationship
study demonstrated that the 7-hydroxy-benzopyran-4-one
structure, which comprises the core isoﬂavone (and other
ﬂavonoids) structure (Figure 1), is key for PPAR activa-
tion [15]. Selective modiﬁcation of this core can form
molecules with dual PPARα-a n dP P A R γ- ligand-binding
activity [15]. From this perspective, isoﬂavones and their
biological metabolites may provide the template for the
next generation of PPAR agonists. Isoﬂavones are naturally
occurring compounds and are safely ingested in amounts up
t o1 0 0m g / d a y .T h i si sa ne x c i t i n ga r e ao fi n v e s t i g a t i o na n d
underscores the possibility that these compounds could be
used therapeutically with a low occurrence of unwanted side
eﬀects. This paper comprises summaries of several aspects of
isoﬂavones: their biochemistry and chemistry, their dietary
intake,bioavailabilityand metabolism, their association with
prevention of chronic disease, and their mechanisms of
action, with special emphasis on PPAR signaling.
2.Biosynthesis and Chemistryof Isoﬂavones
Isoﬂavonesaremembersofthehugefamily ofplantpolyphe-
nols [16]. The polyphenols include bioﬂavonoids (e.g.,
quercetin, catechins, proanthocyanidins) and stilbenoids
(resveratrol). Bioﬂavonoidsconsist of many classes. Depend-
ing on the position of the aromatic B-ring substituent
on the heterocyclic C-ring, they can be broadly separated
into ﬂavonoids and isoﬂavonoids. Both are derived from a
common precursor, phenylalanine. Following the formation
of the ﬂavonoid ring system, the aromatic B-ring migrates
fromthe 2-position to the 3-position catalyzed byan enzyme
restricted to tropical leguminous plants. Edible plants
containing the highest concentrations of isoﬂavones are
soybeans (Glycine max Merrill) [17], kudzu root (Pueraria
lobata)[18],andtheAmerican groundnut(Apiosamericana)
[19].
Theisoﬂavones ineachof theseplantsare principallygly-
cosideconjugatesofdaidzein (7,4 -dihydroxyisoﬂavone) and
genistein(5,7,4 -trihydroxyisoﬂavone).Insoy,theconjugates
are the 7-O-β-D-glucopyranosides with additional esteriﬁ-
cation on the 6  -position of the glucose moiety [20, 21].
The conjugate groups are removed either by fermentation
(to make miso, soy paste, and tempeh) [3] or by intestinal
hydrolysis induced by enzymes in the wall of the intestine
(lactosephlorizinhydrolase)[22]orbybacteria.Inthekudzu
root, C-glucoside conjugates of isoﬂavones (e.g., puerarin,
daidzein 8-C-β-glucopyranoside) predominate [18]. These
are absorbed and excreted without hydrolysis, probably by
Na+-dependent glucose transporter systems.
3.Dietary Intake ofIsoﬂavones
In the Western diet, exposure to isoﬂavones comes mostly
from the use of soy protein to impart useful characteristics
to foods such as low-fat dairy and bakery products, soups,
doughnuts, hamburger buns, canned ﬁsh, and whole turkeys
[23]. In addition, vegetarians and those seeking low-fat diets
consume soy foods such as soy milk, tofu, and textured
vegetable protein. Athletes wanting a high-protein/low-fat
diet use isolated soy protein. The average consumer has
a daily intake of 1-2mg isoﬂavones [24], giving rise to
plasma concentrations from 20to 150nM. Those consuming
1-2 soy meals a day (20–40mg isoﬂavones) have plasma
concentrations ranging from 200 to 3000nM [25]. This wide
range of plasma concentrations is typical of many orally
ingested therapeutics and represents diﬀerences in uptake
from and metabolism in the gut, as well as diﬀerences
in tissue metabolism and urinary and fecal excretion.
Isoﬂavones are also available as over-the-counter dietary
supplements nominally containing 50mg per pill. This
enables considerably higher isoﬂavone intakes. Zeisel and
his colleagues have reported phase 1-dose escalation studies
where daily doses of >1,000mg soy isoﬂavones were used
without reported signiﬁcant hazards [26, 27].
The isoﬂavones in the blood, as for physiological
steroids and many other xenobiotics, are principally β-
glucuronides, with lesser amounts of sulfate esters and only
low (10–100nM) concentrations of their aglycone forms
[28]. Isoﬂavones also undergo metabolism in the large
intestine (Figure 2), and the bacterial products such as
dihydrodaidzein (DHD), O-desmethylangolensin (ODMA),
and S-(-)equolenter the circulation [29]. Whereas DHDand
ODMA are present in most subjects, only 20–30% of people
studied producing S-(-)equol [30, 31]. The discussion above
is presented to underscore the importance of appreciating
the range of concentrations achieved in vivo together with
the knowledge that eﬀects of isoﬂavone consumption may
in fact be mediated by their derivatives from intestinal
bacterial and/orhost cell metabolism, inunderstanding their
mechanisms of action.
In the next sections, we select some of the diseases
that have been shown to be modulated by isoﬂavones andPPAR Research 3
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Figure 2: Metabolites of daidzein. Daidzein is converted by anaerobic bacteria in the large intestine to several metabolites, dihydrodaidzein,
O-desmethylangolensin,andequol.EachofthesemetaboliteshasachiralcenteratC-3dueto thereduction oftheΔ2−3double bond (marked
with a star∗). Equol is found as its S-(-)-equol enantiomer. The chirality of the other daidzein metabolites is not known.
examine the potential sites of involvement of PPAR signaling
and other mechanisms of action.
4.AssociationwithChronic Diseases:
Cellularand Animal Models
4.1. Isoﬂavones and Cardiovascular Disease. Consumption of
isoﬂavones is associated with protection against atheroscle-
rosis, a chronic disease of the vessel wall that underlies the
development of many acute cardiovascular disease events
including myocardial infarction and stroke [32–34]. These
observations are supported by experimental studies in
diverseanimalmodelsofatherosclerosisshowing thatdietary
isoﬂavones can inhibit the disease [35–37]. Interestingly,
if isoﬂavones are administered only in the latter stages of
d i s e a s e ,t h ep r o t e c t i v ee ﬀe c t sa r el o s ts u g g e s t i n gt h a tt h e s e
polyphenols target the early events of atherosclerosis [38].
Less clear are the mechanisms by which isoﬂavones inhibit
atherosclerosis. The two general hypotheses are that these
compounds are antioxidants and/or modulate speciﬁc sig-
naling pathways related to inﬂammation in the vasculature
that aﬀects the disease [39]. With antioxidant eﬀects, the
concept has been that by scavenging reactive species, which
would otherwise promote oxidative damage, isoﬂavones
prevent atherosclerosis. The most cited example in this
case is the inhibition of low-density lipoprotein oxidation,
formation of which is central in atherogenesis [40]. More
recent evidence suggests the hypothesis that isoﬂavones
modulate vascular disease by aﬀecting signaling pathways.
In this paradigm, low (submicromolar) concentrations of
isoﬂavones activate the speciﬁc signaling pathways that
regulate cellular responses to inﬂammation. Two candidate
pathways deﬁned to date which meet this criterion are
activation of ERβ and that of PPARs [41, 42]. We focus the
discussion in this paperon PPARs and note that activation of
PPARα,o r– γ, has been viewed mainly from the perspective
of the regulation of genes that control lipid and glucose
metabolism [43]. However, emerging data suggest critical
roles in modulating vascular inﬂammatory and immune
responses also[44–48].Forexample,PPARγ ligandsdecrease
atherosclerotic lesion size in experimental models [49]. The
anti-inﬂammatory eﬀectsofPPARs appearto be restricted to
the α and γ isotypes, and from the perspective of control-
ling endothelial function, PPARγ ligands inhibit cytokine-
dependentexpression ofadhesion molecules (although these
responses are dependent upon cell type, nature of the
inﬂammatory stimulus, and speciﬁc ligand used) [44, 48].
With respect to isoﬂavones, cell and animal studies have
shown these compounds to be agonists for PPARα-a n d
PPARγ-dependent pathways (see below). For example, the
antidiabetic eﬀects of isoﬂavones are associated with PPARγ
activation in macrophages [49], and with respect to vascular
inﬂammation speciﬁcally our published studies show that
isoﬂavones activate PPARγ in the endothelium and in turn
results in an inhibition of monocyte rolling and adhesion, a
key step in inﬂammation [13, 14]( Figure 3).
4.2.Cancer. Littleconsiderationhasbeengivenbythecancer
research community to possible roles of isoﬂavone-directed
PPAR signaling [50]. Nonetheless, genistein has been shown
to lower the production of prostaglandin E2 by MDA-MB-
231 human breast cancer cells and to reduce invasiveness4 PPAR Research
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Figure 3: Isoﬂavones activate the PPARγ promoter: cultured
endothelial cells were transfected with plasmids containing the
promoter response elements for PPARγ (PPRE) or PPRE-negative
plasmids and then exposed to indicated isoﬂavones (1μM) and
vehicle controls. Data are expressed as fold of the control (i.e.,
relative to no isoﬂavone-treated cells) and are means ± SEM (n =
3–6). ∗Diﬀerent from control, P ≤ .005. They illustrate the ability
of isoﬂavones to stimulate transcription of PPARγ-regulated genes.
Genistein, daidzein, and biochanin A (4 -methoxygenistein) have
promoter activities comparable to rosiglitazone (ﬁgure reproduced
with permission by the Journal of Nutrition).
of these cells [51]. The eﬀect of eicosapentaenoic and
docosahexaenoic acids in activating PPARγ was dependent
on genistein [52]. Eﬀects of isoﬂavones on lipid signaling
may be an important aspect of carcinogenesis and tumor
invasiveness.
4.3. Lymphangioleiomyomatosis. This rare lung disease
aﬀects 1 in 100,00 women [53]. It is caused by migration
of uterine smooth muscle cells to the lung where they
form cysts and cause loss of lung function. Many of the
women have mutations in tuberin (TSC1) and harmartin
(TSC2) that form the tuberous sclerosis protein complex
[54]. The TSC1/TSC2 complex is a critical player in the
control of mTOR, a master regulator of cellular metabolism.
ThemigrationofELT-3cellstothelungsinarodentmodelof
lymphangioleiomyomatosis is driven by 17β-estradiol [55].
There is a concernthat the isoﬂavones may mimic this action
of estrogen [56]. However, a recent study on estrogen pro-
liferation of ELT-3s cell also showed that genistein blocked
this action of 17β-estradiol [57]. Importantly, genistein’s
inhibitory eﬀect was in turn attenuated by the PPARγ
inhibitor GW9662 [57]. This underscores the likelihood that
theactionofisoﬂavonesinmammals includingmanismulti-
factorialandthatPPARsignalingisatargetoftheisoﬂavones.
4.4. Metabolic Syndrome. There is an extensive literature
going back to 2001 linking soy and its isoﬂavones to
lipid metabolism and the metabolic syndrome. Harmon
and Harp showed that genistein inhibited the proliferation
and diﬀerentiation of 3T3-L1 cells, a preadipocyte cell
line [58]. Genistein also increased lipolysis in these cells
[58]. These investigators also demonstrated that genistein
blocked the DNA binding and transcriptional activity of
the CCAAT-/enhancer-binding protein beta by promoting
the production of C/EBP homologous protein [58]. This in
turn impacted PPARγ protein expression [58]. A diﬀerential
eﬀect of genistein was observed in mesenchymal progenitor
cells and revealed opposing eﬀects of estrogen receptor and
PPARγ pathways [59]. At low genistein concentrations, the
estrogen-like eﬀect was observed, whereas at micromolar
concentrations, PPARγ activation predominated [59]. This
r a i s e st h ei s s u eo fw h i c ho ft h e s et w oe ﬀects are observed
in vivo. Mezei et al. showed that diabetic Zucker rats fed a
high isoﬂavone diet have lower triglyceride and cholesterol
concentrations [49]. They also demonstrated that genistein
and daidzein signiﬁcantly increased PPARα-a n dP P A R γ-
directed gene expression in murine RAW 264.7 cells [49].
5.Isoﬂavone Mechanisms ofAction
Whereas isoﬂavones and other phytoestrogens were origi-
nally studied because of their estrogenic activity in certain
species, it has become clear that they have additional
mechanisms of action that may override their estrogenic
eﬀects. Genistein was identiﬁed in 1987 as a potent inhibitor
of the epidermal growth factor receptor tyrosine kinase
[60]. This was important to the cancer ﬁeld at that time
since genistein, unlike comparable, chemically synthesized
tyrosine kinase inhibitors, did not have toxic eﬀects at
the doses needed for tyrosine kinase inhibition. Genistein
has been widely used as a pharmacological tyrosine kinase
inhibitoroftenwithoutvalidationthatanychangesinprotein
phosphorylation observed on Western blots were due to
direct genistein inhibition of phosphorylation as opposed to
indirect eﬀects due to a reduction in the parent protein.
Like other polyphenols, many studies have shown that
isoﬂavones can scavenge various reactive oxygen species
(RO), reactive nitrogen species (RN) or reactive chlorine
species (RCS) that are formed endogenously during the
innate immune response, but which also cause tissue
injury that leads to the development of acute and chronic
inﬂammatory disease [61–69]. In doingso, the “antioxidant”
eﬀect of isoﬂavones has been proposed to mediate their
cytoprotective eﬀects. This concept is supported by human
studies showing a decrease in plasma markers of lipid per-
oxidation after consuming isoﬂavones [70]. Concerns over
the antioxidant hypothesis include the discrepancy between
isoﬂavone concentrations achieved in the circulation (0.1–
1μM) after dietary ingestion and those required to observe
a signiﬁcant inhibition of oxidative damage ex vivo and
in vitro with the latter typically being ≥10-fold higher.
Another consideration is that although the primary reactive
species may be scavenged, the products of the reaction
and their reactivities must also be considered. With respect
to isoﬂavones, we have shown that upon reacting with
lipid peroxyl radicals (which inhibits lipid peroxidation),
the corresponding isoﬂavone oxidation product (a phenoxyl
radical) is not inert but can also promote oxidative damagePPAR Research 5
itself[67].Interestingly, the presence of ascorbate can reform
the parent isoﬂavone from this intermediate allowing the
isoﬂavone to act as an antioxidant in a “catalytic” manner
which would also allow it to exert signiﬁcant antioxidant
eﬀects in vivo at low concentrations [65, 67]. Finally,
it is important to note that a key variable in assessing
mechanisms of action is the fact that isoﬂavone preparations
are not typically homogenous but contain complex mixtures
of structurally distinct molecules. Moreover, it is now
apparent that isoﬂavone metabolism can give rise to an
array of products which themselves have diﬀerent biological
activities. Forexample,equolisproducedbytheactionofgut
microﬂora on ingested daidzein (see above). Interestingly,
the composition of this microﬂora is not homogenous
across the human population,and recentstudies suggest that
“equol producers” receive the health beneﬁts of isoﬂavones
consumption more than “equol nonproducers” [71]. In a
similar fashion, reaction between isoﬂavones and reactive
species in vivo can form novel isoﬂavone derivatives. For
example, reaction with the RNS peroxynitrite or with
the RCS hypochlorous acid form mono- or dinitrated or
chlorinated isoﬂavones, respectively [61,62]. We haveshown
that nitration and/or chlorination changes the antioxidant
activity of the products compared to the parent isoﬂavones
and in some cases increases antioxidant potency [62]. In
this case, the ﬁrst reactions would scavenge the reactive
species but in addition also form more potent antioxidant
isoﬂavones. We postulate that such mechanisms described
a b o v em a yr e c o n c i l et h ed i ﬀerences between dose-response
relationships for antioxidant eﬀects of isoﬂavones in vivo
versus in vitro [72].
Attempts to produce animal diets free of phytoestrogens
to provide more consistency in experiments designed to
investigate the eﬀects of added phytoestrogens had an unex-
pected, but critically important, eﬀect. The animals showed
had a marked increase in weight with the phytoestrogen-free
diets, mostly in the form of abdominal fat [73]. This result
suggested that phytoestrogens have a role in preventing the
metabolic syndrome which in turnpoints to possible activity
in PPAR signaling.
6.Isoﬂavonesand Cell Signaling:
ActivationofPPARs
Several studies have now developed the concept that
activation of either PPARα and/or PPARγ is key to the
biological eﬀects of isoﬂavones [42]. This has been demon-
strated in diverse experimental settings and cell types
(including endothelium, monocytes, HepG2, bone mar-
row stromal cells) and importantly occurs at biologically
relevant isoﬂavone concentrations. Using constructs con-
taining either PPARα-/PPARγ- ligand binding-domains or
sequences corresponding to promoter response elements,
several independent studies [13, 42, 49, 74]h a v ep r o v i d e d
molecular evidence that isoﬂavones can stimulate PPARα/γ-
dependent gene expression. Importantly, this results in
diverse functional eﬀects that include modulating adipo-
genesis to regulating cellular responses to inﬂammation.
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Figure 4: Isoﬂavones inhibit TNFα-induced monocyte adhesion
to the vascular wall via activation of PPARγ. Both genistein
(1μM) and rosiglitazone (2μM) signiﬁcantly reduced TNFα-
induced monocyteadhesionto thevascularwallcomparedto TNFα
alone. This inhibition was reversed by the PPARγ antagonist, GW
9662 (5μM), revealing that genistein’s inhibitory eﬀect was PPARγ
dependent (reproduced with permission by the American Journal of
Physiology).
Moreover, these cellular responses are inhibited by pharma-
cologically (using PPAR inhibitors) or molecularly (using
siRNA-mediated downregulation of PPAR expression) based
strategies to aﬀect PPAR signaling [13, 14, 42, 49, 74]. The
latteriscritical,sincetheliteratureisrepletewithexamplesof
putative PPAR ligands that subsequent studies have shown,
i nf a c t ,t om e d i a t ec e l l u l a ra ﬀects via PPAR-independent
mechanisms. Figure 3 illustrates these points with data from
our previous studies [13, 14] showing that in endothelial
cells, isoﬂavones stimulate PPARγ-dependent transcription
of genes containing the PPARγ response elements in their
promoter, and this results in the inhibition of subsequent
inﬂammatory cytokine(TNFα)-dependentmonocyterolling
and adhesion (Figure 4).
Interestingly, a survey of the literature does not reveal
a clear association between the activation of either PPARα
or PPARγ and the mediation of a biological response with
evidence for both in mediating anti-inﬂammatory eﬀects
of isoﬂavones reported. For example red clover isoﬂavones
inhibiting cytokine release from LPS activated macrophages
via PPARα [75]. Similarly, PPARα activation has been
discussed in the context of how isoﬂavones may prevent
inﬂuenza [76]. On the other hand, anti-inﬂammatory eﬀects
have been shown to be PPARγ dependent also including
inhibition of amyloid-beta-dependent cytokineformation in
astrocytes [77]. Our studies have shown that PPARγ,b u t
not PPARα, is required for isoﬂavone-dependent inhibition
of leukocyte rolling and adhesion to activated endothelial
cells [13, 14]( Figure 4). Otherreports in deﬁned cell systems
have also reported selective activation of one PPAR isoform
and not the other. For example, methanolic (IF) extracts
from soybean seeds stimulated transcriptional activity of
PPARα,b u tn o tP P A R γ, genes in monocyte U937 cells [78].
As the above discussion suggests, a detailed understanding6 PPAR Research
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Figure 5: Regulation of isoﬂavone-dependent activation of PPAR signaling. Isoﬂavone consumption has been shown to activate ERβ-,
PPARα-, or PPARγ-dependent signalingpathwaysandin this way mayexert control overdiverse biologicalprocesses that are associatedwith
health beneﬁts of consuming these compounds. Summarized in this ﬁgure are the key factors that likely control how isoﬂavones modulate
signaling. The core 7-hydroxy-benzopyran-4-one structure has recently been shown to be important for PPARα and PPARγ activation,
and importantly this core is present in many plant-derived isoﬂavones that comprise natural and commercial preparations (shown are the
structures of genistein, daidzein, and biochanin A as examples). Also indicated is the 7-hydroxy group on the A-ring that has been shown
to be critical for PPARα and PPARγ activation [13, 14]). Modiﬁcation of isoﬂavones,for example, via reactions with inﬂammatory oxidants
can form a variety of halogenated isoﬂavones which in turn can alter the eﬃcacy of isoﬂavone-dependent activation of signaling (shown as
an example is 3 -chlorodaidzein). Note that multiple positional isomers of chlorine and bromine (other endogenous halogens and nitration
p r o d u c t sa r ep o s s i b l e[ 13, 61–63]. Moreover, gut microﬂora metabolism has been shown to be important in producing equol from daidzein
and may have cardiovascular protective eﬀects. We propose that a better understanding of isoﬂavone metabolism, the modiﬁcations that
occur, and how they inﬂuence activation of ER/PPAR pathways is central to elucidating molecular mechanisms by which these compounds
aﬀect disease. Additional andimportant factors that will dictate thebiologicalresponseto isoﬂavonesinclude expression proﬁles andrelative
activities and interactions between of ERβ-, PPARα-, and PPARγ-dependent pathways.
of how isoﬂavones activate PPARα or PPARγ is lacking. It
is clear, however, that isoﬂavones can activate both PPARα
and PPARγ, and it is not surprising then that a number
of studies have documented roles for these polyphenols
in preventing diabetes and the metabolic syndrome with
mechanisms ranging from improving lipid homeostasis to
insulin sensitivity [49, 79–86].
The discussion above serves to underscore the hetero-
geneity of responses elicited by isoﬂavone-mediated acti-
vation of PPARs. It remains unclear to date why in some
cases both PPARα and PPARγ are activated, while in others
why only one PPAR isoform is activated versus the other.
Potential factors/variables that may modulate isoﬂavone-
dependent activation of PPARs and signaling in general
include the cell type, the presence/absence of PPAR co-
activators, competition between ERα and PPAR signaling,
and the dose and composition of isoﬂavones preparations
(see Figure 5). For example, Dang elegantly showed that low
concentrations (<1μM) of genistein stimulated osteogenesis
whilst inhibiting adipogenesis in mesenchymal progenitor
cells via ER mechanisms, whereas at slightly higher con-
centrations, the opposite response was observed which was
mediated by PPARγ activation [80]. Similarly, isoﬂavone-
dependent activation of PPARγ was shown to be important
in theinhibition ofestradiol-induced proliferation ofuterine
leiomyoma [57]. These latter examples highlight the poten-
tialforisoﬂavonestomodulateestrogensignalingviaindirect
mechanisms and suggest a complexcross-talk between PPAR
and ER signaling, that is regulated by isoﬂavones (Figure 5).
With respect to isoﬂavones’ type, studies have shown that
several structurally distinct isoﬂavones can activate PPARs
with similar eﬃcacies [13]. It is not clear how the presence of
diﬀerentisoﬂavoneswouldaﬀectPPARactivation. Ifadditive
or synergistic, however, one can speculate that the eﬀective
dose of a given isoﬂavone to activate PPARα/γ would be even
lower in the context of a complex mixture as occurs during
dietary exposure. In this scenario of exposure to multiple
diﬀerent isoﬂavones, we speculate that PPARα/PPARγ acti-
vation represents the primary signaling pathways aﬀected
by these compounds. Finally,w en o t et h a to t h e rf a c t o r s
may also modulate PPAR activation eﬃcacy as illustrated
by dietary exposure studies showing that soy protein alone
increased PPARα, but this response was increased further in
t h ep r e s e n c eo fi s o ﬂ a v o n e s[ 87].
7.RemainingQuestionsand
Future Perspectives
The potential role of PPARs to mediate biological actions of
isoﬂavonesis gaining appreciation.Lesscleararethemolecu-
lar mechanisms thatareinvolved.Doisoﬂavones bindPPARsPPAR Research 7
directly and/or do they aﬀect PPAR signaling indirectly?
Structure-activity relationship studies clearly suggest the
former, but the latter possibility should also be considered.
For example, oxidized fatty acids have been suggested to be
potent PPARγ agonists and isoﬂavones may inﬂuence these
by aﬀecting redox reactions. What controls the dual eﬀects
of isoﬂavones as PPARα and PPARγ agonists? What are the
downstream targets of isoﬂavone-mediated PPAR activation,
are they unique or do they overlap with PPAR activation by
syntheticagonists?Thisisanintriguingquestion,sincetoour
knowledgeisoﬂavonesaretheonlyclassofmoleculesthatcan
activatebothERβandPPARs,raisingthequestionofwhether
there is cross-talk between ERβ and PPARs activation, and
howthisisregulated.Coupledwith abetterunderstandingof
the potential for antagonistic, additive, or synergistic eﬀects
betweenstructurally distinct isoﬂavonesin activating PPARs,
we feel that addressing these questions is likely to reveal
novel insights into how these polyphenols inﬂuence diverse
biological processes.
Acknowledgments
Funds for research on isoﬂavones have come through a sub-
contract from the Purdue University as part of a grant from
the National Center for Complementary and Alternative
Medicine and the Oﬃce of Dietary Supplements, National
Institutes of Health (P50 AT00477, C.M. Weaver, PI) to
the Purdue University-University of Alabama Botanicals
Center for Age-Related Disease and from a grant from the
National Cancer Institute (U54 CA100949, SB, PI) to the
University of Alabama at Birmingham Center for Nutrient-
Gene Interaction.
References
[ 1 ] M .A .K l e i n ,R .L .N a h i n ,M .J .M e s s i n ae ta l . ,“ G u i d a n c ef r o m
an NIH workshopon designing,implementing,and reporting
clinical studies of soy interventions,” Journal of Nutrition,v o l .
140, no. 6, pp. 1192S–1204S, 2010.
[2] K. K. Rozman, J. Bhatia, A. M. Calafat et al., “NTP-CERHR
expert panel report on the reproductive and developmental
toxicity of soy formula,” Birth Defects Research Part B, vol. 77,
no. 4, pp. 280–397, 2006.
[ 3 ]L .C o w a r d ,N .C .B a r n e s ,K .D .R .S e t c h e l l ,a n dS .B a r n e s ,
“Genistein, daidzein, and their beta-glycoside conjugates—
antitumor isoﬂavones in soybean foods from American and
Asian diets,” Journal of Agricultural and Food Chemistry,v o l .
41, no. 11, pp. 1961–1967, 1993.
[4] P. A. Murphy, T. Song, G. Busemanet al., “Isoﬂavonesin retail
and institutional soy foods,” Journal of Agricultural and Food
Chemistry, vol. 47, no. 7, pp. 2697–2704, 1999.
[5] W.N.Jeﬀerson,E.Padilla-Banks,andR.R.Newbold, “Disrup-
tion of the female reproductive system by the phytoestrogen
genistein,”Reproductive Toxicology,vol.23,no.3,pp. 308–316,
2007.
[ 6 ]N .R .A d a m s ,“ D e t e c t i o no ft h ee ﬀects of phytoestrogens on
sheep and cattle,” Journal of Animal Science,v o l .7 3 ,n o .5 ,p p .
1509–1515, 1995.
[7] K. D. R. Setchell, S. J. Gosselin, M. B. Welsh et al., “Dietary
estrogens—a probable cause of infertility and liver disease in
captive cheetahs,”Gastroenterology,vol.93,no.2,pp.225–233,
1987.
[8] M. H. Court and D. J.Greenblatt, “Molecular genetic basis for
deﬁcient acetaminophen glucuronidation by cats: UGT1A6 is
a pseudogene, and evidence for reduced diversity of expressed
hepaticUGT1Aisoforms,”Pharmacogenetics,vol.10,no.4,pp .
355–369, 2000.
[ 9 ] S .B a r n e s ,C .G r u b b s ,K .D .S e t c h e l l ,a n dJ .C a r l s o n ,“ S o y b e a n s
inhibit mammarytumors in models ofbreast cancer,” Progress
in Clinical and BiologicalResearch,vol.347,pp.239–253,1990.
[10] T. M. Cho, N. Peng, J. T. Clark et al., “Genistein attenuates the
hypertensive eﬀects ofdietary NaClinhypertensive malerats,”
Endocrinology, vol. 148, no. 11, pp. 5396–5402, 2007.
[11] A. M. Schuler, S. Barnes, B. A. Gower, and P. A. Wood,
“Dietary phytoestrogens increase metabolic resistance (cold
tolerance) in long-chain acyl-CoA dehydrogenase-deﬁcient
mice,” Journal of Nutrition, vol. 134, no. 5, pp. 1028–1031,
2004.
[ 1 2 ]N .K .S a l a m ,T .H .W .H u a n g ,B .P .K o t a ,M .S .K i m ,Y .
Li, and D. E. Hibbs, “Novel PPAR-gamma agonists identiﬁed
from a natural product library: a virtual screening, induced-
ﬁt docking and biological assay study,” Chemical Biology and
Drug Design, vol. 71, no. 1, pp. 57–70, 2008.
[13] B. K. Chacko, R. T. Chandler, T. L. D’Alessandro et al., “Anti-
inﬂammatoryeﬀects of isoﬂavonesare dependent on ﬂow and
human endothelial cell PPARγ,” Journal of Nutrition, vol. 137,
no. 2, pp. 351–356, 2007.
[14] B. K. Chacko, R. T. Chandler, A. Mundhekar et al., “Revealing
anti-inﬂammatory mechanisms of soy isoﬂavones by ﬂow:
modulation of leukocyte-endothelial cell interactions,” Amer-
ican Journal of Physiology—Heart and Circulatory Physiology,
vol. 289, no. 2, pp. H908–H915, 2005.
[15] A. Matin, N. Gavande, M. S. Kim et al., “7-Hydroxy-
benzopyran-4-one derivatives: a novel pharmacophore of
peroxisome proliferator-activated receptor α and -γ (PPARα
and γ) dual agonists,” Journal of Medicinal Chemistry, vol. 52,
no. 21, pp. 6835–6850, 2009.
[16] J.B. Harborne, Ed., The Flavonoids: Advances in Research Since
1986, Chapman & Hall, New York, NY, USA, 1994.
[17] C. L. Aguiar, A. S. Baptista, S. M. Alencar, R. Haddad, and
M. N. Eberlin, “Analysis of isoﬂavonoids from leguminous
plant extracts by RPHPLC/DAD and electrospray ionization
mass spectrometry,” International Journal of Food Sciences and
Nutrition, vol. 58, no. 2, pp. 116–124, 2007.
[18] J. K. Prasain, K. Jones, M. Kirk et al., “Proﬁling and
quantiﬁcation of isoﬂavonoids in kudzu dietary supplements
by high-performance liquid chromatography andelectrospray
ionization tandem mass spectrometry,” Journal of Agricultural
and Food Chemistry, vol. 51, no. 15, pp. 4213–4218, 2003.
[19] S. Barnes, C. C. Wang,M. Kirk et al.,“HPLC-massspectrome-
try of isoﬂavonoidsin soy and the american groundnut, Apios
americana,” Advances in Experimental Medicine and Biology,
vol. 505, pp. 77–88, 2002.
[20] S. Kudou, Y. Fleury, D. Welti et al., “Malonyl isoﬂavone glyco-
sides in soybean seeds (Glycine max MERRILL),” Agricultural
and Biological Chemistry, vol. 55, pp. 2227–2233, 1991.
[ 2 1 ]S .B a r n e s ,M .K i r k ,a n dL .C o w a r d ,“ I s o ﬂ a v o n e sa n dt h e i r
conjugates in soy foods: extraction conditions and analysis by
HPLC-mass spectrometry,” Journal of Agricultural and Food
Chemistry, vol. 42, no. 11, pp. 2466–2474, 1994.
[22] A. J. Day, F. J. Ca˜ nada, J. C. D´ ıaz et al., “Dietary ﬂavonoid
and isoﬂavone glycosides are hydrolysed by the lactase site of
lactasephlorizinhydrolase,”FEBS Letters,vol.468,no.2-3,pp.
166–170, 2000.8 PPAR Research
[23] P. L. Horn-Ross, S. Barnes, M. Lee et al., “Assessing phytoe-
strogen exposure in epidemiologic studies: development of a
database (United States),” Cancer Causes and Control, vol. 11,
no. 4, pp. 289–298, 2000.
[24] O .K .C hu n,S.J .C hu ng,andW .O .Song,“ U rinaryisoﬂa v one s
and their metabolites validate the dietary isoﬂavoneintakes in
US adults,” Journal of the American Dietetic Association,v o l .
109, no. 2, pp. 245–254, 2009.
[25] D. Urban, W. Irwin, M. Kirk et al., “The eﬀect of isolated soy
protein on plasma biomarkers in elderly men with elevated
serum prostate speciﬁc antigen,” Journal of Urology, vol. 165,
no. 1, pp. 294–300, 2001.
[26] M. G. Busby, A. R. Jeﬀcoat, L. T. Bloedon et al., “Clinical char-
acteristics and pharmacokinetics of puriﬁed soy isoﬂavones:
single-dose administration to healthy men,” American Journal
of Clinical Nutrition, vol. 75, no. 1, pp. 126–136, 2002.
[27] L.T.Bloedon,A.Robert Jeﬀcoat,W.Lopaczynskietal.,“Safety
and pharmacokinetics of puriﬁed soy isoﬂavones: single-dose
administrationto postmenopausalwomen,”American Journal
of Clinical Nutrition, vol. 76, no. 5, pp. 1126–1137, 2002.
[ 2 8 ]C .O .C i m i n o ,S .R .S h e l n u t t ,M .J .J .R o n i s ,a n dT .M .
Badger, “An LC-MS method to determine concentrations of
isoﬂavones and their sulfate and glucuronide conjugates in
urine,”ClinicaChimicaActa,vol.287,no.1-2,pp.69–82,1999.
[29] G. E. Kelly, C. Nelson, M. A. Waring, G. E. Joannou, and A.
Y. Reeder, “Metabolites of dietary (soya) isoﬂavonesin human
urine,” Clinica Chimica Acta, vol. 223, no. 1-2, pp. 9–22, 1993.
[30] M. Axelson, J. Sjovall, B. E. Gustaﬀs o n ,a n dK .D .R .S e t c h e l l ,
“Soya. A dietary source of non-steroidal oestrogen equol in
man and animals,” Journal of Endocrinology, vol. 102, no. 1,
pp. 49–56, 1984.
[31] C.A tkinson,K.M.N ewton,E.J.AielloBowles,M.Y ong,andJ.
W. Lampe, “Demographic, anthropometric, and lifestyle fac-
tors and dietary intakes in relation to daidzein-metabolizing
phenotypes among premenopausal women in the United
States,” American Journal of Clinical Nutrition, vol. 87, no. 3,
pp. 679–687, 2008.
[32] L. Wroblewski Lissin and J. P. Cooke, “Phytoestrogens and
cardiovascular health,” Journal of the American College of
Cardiology, vol. 35, no. 6, pp. 1403–1410, 2000.
[33] M. Navab, A. M. Fogelman, J. A. Berliner et al., “Pathogenesis
ofatherosclerosis,”American Journal of Cardiology, vol.76,no.
9, pp. 18C–23C, 1995.
[34] F. Ursini, F. Tubaro, J. Rong, and A. Sevanian, “Optimization
of nutrition: polyphenols and vascular protection,” Nutrition
Reviews, vol. 57, no. 8, pp. 241–249, 1999.
[35] M. S. Anthony, T. B. Clarkson, and J. K. Williams, “Eﬀects
of soy isoﬂavones on atherosclerosis: potential mechanisms,”
American Journal of Clinical Nutrition,v o l .6 8 ,n o .6 ,p p .
1390S–1393S, 1998.
[36] M. J. Tikkanen and H. Adlercreutz, “Dietary soy-derived
isoﬂavone phytoestrogens: could they have a role in coronary
heart disease prevention?” Biochemical Pharmacology, vol. 60,
no. 1, pp. 1–5, 2000.
[37] J. Yamakoshi, M. K. Piskula, T. Izumi et al., “Isoﬂavone
aglycone-rich extract without soy protein attenuates
atherosclerosis development in cholesterol-fed rabbits,”
Journal of Nutrition, vol. 130, no. 8, pp. 1887–1893, 2000.
[38] M. M. Averill, B. J. Bennett, M. Rattazzi et al., “Neither
antioxidants nor genistein inhibit the progression of estab-
lished atherosclerotic lesions in older apoE deﬁcient mice,”
Atherosclerosis, vol. 203, no. 1, pp. 82–88, 2009.
[39] S. Barnes, B. Boersma, R. Patel et al., “Isoﬂavonoids and
chronicdisease:mechanismsofaction,”BioFactors,vol.12,no.
1–4, pp. 209–215, 2000.
[40] J. A. Berliner and J. W. Heinecke, “The role of oxidized
lipoproteins in atherogenesis,” Free Radical Biology and
Medicine, vol. 20, no. 5, pp. 707–727, 1996.
[41] G. G. J. M. Kuiper, J. G. Lemmen, B. Carlsson et al.,
“Interaction of estrogenic chemicals and phytoestrogens with
estrogen receptor β,” Endocrinology,vol.139,no.10,pp. 4252–
4263, 1998.
[42] M. L. Ricketts, D. D. Moore, W. J. Banz, O. Mezei, and N. F.
Shay, “Molecular mechanisms of action of the soy isoﬂavones
includes activation of promiscuous nuclear receptors. A
review,” Journal of Nutritional Biochemistry,v o l .1 6 ,n o .6 ,p p .
321–330, 2005.
[43] J. Berger and J. A. Wagner, “Physiological and therapeutic
roles of peroxisome proliferator-activated receptors,” Diabetes
Technology and Therapeutics, vol. 4, no. 2, pp. 163–174, 2002.
[44] S. M. Jackson, F. Parhami, X. P. Xi et al., “Peroxi-
some proliferator-activated receptor activators target human
endothelial cells to inhibit leukocyte-endothelial cell interac-
tion,” Arteriosclerosis, Thrombosis, and Vascular Biology,v o l .
19, no. 9, pp. 2094–2104, 1999.
[45] J. Plutzky, “Peroxisome proliferator-activated receptors as
therapeutic targets in inﬂammation,” Journal of the American
College of Cardiology, vol. 42, no. 10, pp. 1764–1766, 2003.
[46] Y. Liu,Y. Zhu,F. Rannou et al.,“Laminarﬂow activates perox-
isome proliferator-activated receptor-γ in vascular endothelial
cells,” Circulation, vol. 110, no. 9, pp. 1128–1133, 2004.
[47] V. Pasceri, H. D. Wu, J. T. Willerson, and E. T. H. Yeh,
“Modulation of vascular inﬂammation in vitro and in vivo
by peroxisome proliferator-activated receptor-γ activators,”
Circulation, vol. 101, no. 3, pp. 235–238, 2000.
[48] N. Marx, H. Duez, J. C. Fruchart, and B. Staels, “Peroxisome
proliferator-activated receptors and atherogenesis: regulators
of gene expression in vascular cells,” Circulation Research,v o l .
94, no. 9, pp. 1168–1178, 2004.
[ 4 9 ]O .M e z e i ,W .J .B a n z ,R .W .S t e g e r ,M .R .P e l u s o ,T .A .
Winters, and N. Shay, “Soy isoﬂavones exert antidiabetic and
hypolipidemic eﬀects through the PPAR pathways in obese
Zuckerrats andmurineRAW 264.7 cells,” Journal of Nutrition,
vol. 133, no. 5, pp. 1238–1243, 2003.
[ 5 0 ]L .H i l a k i v i - C l a r k e ,C .W a n g ,M .K a l i l ,R .R i g g i n s ,a n dR .G .
Pestell, “Nutritional modulation of the cell cycle and breast
cancer,” Endocrine-Related Cancer, vol. 11, no. 4, pp. 603–622,
2004.
[51] E. Horia and B. A. Watkins, “Complementary actions of
docosahexaenoicacid andgenistein onCOX-2, PGE andinva-
siveness in MDA-MB-231 breast cancer cells,” Carcinogenesis,
vol. 28, no. 4, pp. 809–815, 2007.
[52] H. Nakagawa, D. Yamamoto, Y. Kiyozuka et al., “Eﬀects
of genistein and synergistic action in combination with
eicosapentaenoic acid on the growth of breast cancer cell
lines,” J o u r n a lo fC a n c e rR e s e a r c ha n dC l i n i c a lO n c o l o g y ,v o l .
126, no. 8, pp. 448–454, 2000.
[53] W. K. Steagall, A. M. Taveira-DaSilva, and J. Moss, “Clinical
and molecular insights into lymphangioleiomyomatosis,”Sar-
coidosis Vasculitis and Diﬀuse Lung Diseases,v o l .2 2 ,n o .1 ,p p .
S49–S66, 2005.
[ 5 4 ]D .A .M u z y k e w i c z ,A .S h a r m a ,V .M u s e ,A .L .N u m i s ,J .
R a j a g o p a l ,a n dE .A .T h i e l e ,“ T S C 1a n dT S C 2m u t a t i o n s
in patients with lymphangioleiomyomatosis and tuberous
sclerosis complex,” Journal of Medical Genetics,v o l .4 6 ,n o .7 ,
pp. 465–468, 2009.PPAR Research 9
[55] J. J. Yu, V. A. Robb, T. A. Morrison et al., “Estrogen promotes
the survival and pulmonary metastasis of tuberin-null cells,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 106, no. 8, pp. 2635–2640, 2009.
[56] S.Barnes,“The biochemistry, chemistry andphysiology ofthe
isoﬂavones in soybeans and their food products,” Lymphatic
Research and Biology, vol. 8, no. 1, pp. 89–98, 2010.
[57] A. Miyake, T. Takeda, A. Isobe et al., “Repressive eﬀect
of the phytoestrogen genistein on estradiol-induced uterine
leiomyoma cell proliferation,” Gynecological Endocrinology,
vol. 25, no. 6, pp. 403–409, 2009.
[ 5 8 ] A .W .H a r m o n ,Y .M .P a t e l ,a n dJ .B .H a r p ,“ G e n i s t e i ni n h i b i t s
CCAAT/enhancer-binding protein β (C/EBPβ)a c t i v i t ya n d
3T3-L1 adipogenesis by increasing C/EBP homologous pro-
tein expression,” Biochemical Journal, vol. 367, no. 1, pp. 203–
208, 2002.
[59] Q. C. Liao, Y. L. Li, Y. F. Qin et al., “Inhibition of adipocyte
diﬀerentiation by phytoestrogen genistein through a potential
downregulation of extracellular signal-regulated kinases 1/2
activity,” Journal of Cellular Biochemistry, vol. 104, no. 5, pp.
1853–1864, 2008.
[60] T. Akiyama, J. Ishida, S. Nakagawa et al., “Genistein, a
speciﬁc inhibitor of tyrosine-speciﬁc protein kinases,” Journal
of Biological Chemistry, vol. 262, no. 12, pp. 5592–5595, 1987.
[61] B. J. Boersma, R. P. Patel, M. Kirk et al., “Chlorination and
nitration of soy isoﬂavones,” Archives of Biochemistry and
Biophysics, vol. 368, no. 2, pp. 265–275, 1999.
[62] B. J. Boersma, T. D’Alessandro, M. R. Benton et al.,
“Neutrophil myeloperoxidase chlorinates and nitrates soy
isoﬂavones and enhances their antioxidant properties,” Free
Radical Biology and Medicine, vol. 35, no. 11, pp. 1417–1430,
2003.
[63] T. D’Alessandro, J. Prasain, M. R. Benton et al., “Polyphenols,
inﬂammatory response, and cancer prevention: chlorination
ofisoﬂavonesbyhumanneutrophils,”JournalofNutrition,v ol.
133, no. 11, pp. 3773S–3777S, 2003.
[64] W. S. Xiang, J. Zhang, J. D. Wang et al., “Isolation and
identiﬁcation of chlorinated genistein from Actinoplanes sp.
HBDN08 with antioxidant and antitumor activities,” Journal
of Agricultural and Food Chemistry, vol. 58, no. 3, pp. 1933–
1938, 2010.
[65] J.Hwang,A.Sevanian,H.N.Hodis,andF.Ursini,“Synergistic
inhibition of LDL oxidation by phytoestrogens and ascorbic
acid,” Free Radical Biology and Medicine,vol.29,no. 1, pp. 79–
89, 2000.
[66] N. Kerry and M. Abbey, “The isoﬂavone genistein inhibits
copper and peroxyl radical mediated low density lipoprotein
oxidationinvitro,”Atherosclerosis, vol.140,no.2,pp.341–347,
1998.
[67] R. P. Patel, B. J. Boersma, J. H. Crawford et al., “Antioxidant
mechanismsofisoﬂavonesinlipid systems:paradoxicaleﬀects
of peroxyl radical scavenging,” Free Radical Biology and
Medicine, vol. 31, no. 12, pp. 1570–1581, 2001.
[68] M. B. Ruiz-Larrea, A. R. Mohan, G. Paganga, N. J. Miller,
G. P. Bolwell, and C. A. Rice-Evans, “Antioxidant activity of
phytoestrogenicisoﬂavones,”FreeRadical Research,vol.26,no.
1, pp. 63–70, 1997.
[69] M. J. Tikkanen, K. W¨ ah¨ al¨ a, S. Ojala, V. Vihma, and H.
Adlercreutz, “Eﬀect of soybean phytoestrogen intake on low
density lipoprotein oxidation resistance,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 95, no. 6, pp. 3106–3110, 1998.
[70] H. Wiseman, J. D. O’Reilly, H. Adlercreutz et al., “Isoﬂavone
phytoestrogens consumed in soy decrease F-isoprostane
concentrations and increase resistance oflow-density lipopro-
tein to oxidation in humans,” American Journal of Clinical
Nutrition, vol. 72, no. 2, pp. 395–400, 2000.
[71] K. D. R. Setchell, N. M. Brown, and E. Lydeking-Olsen, “The
clinical importance of the metabolite equol—a clue to the
eﬀectiveness of soy and its isoﬂavones,” Journal of Nutrition,
vol. 132, no. 12, pp. 3577–3584, 2002.
[72] S. BarnesandH. Kim,“Cautionsandresearch needs identiﬁed
at the equol, soy, and menopause research leadership confer-
ence,” Journal of Nutrition, vol. 140, no. 7, pp. 1390S–1394S,
2010.
[73] C. R. Cederroth, M. Vinciguerra, F. K¨ uhne et al., “A
phytoestrogen-rich diet increases energy expenditure and
decreases adiposity in mice,” Environmental Health Perspec-
tives, vol. 115, no. 10, pp. 1467–1473, 2007.
[74] Z.-C. Dang, V. Audinot, S. E. Papapoulos, J. A. Boutin, and C.
W. G. M. L¨ owik, “Peroxisome proliferator-activated receptor
γ (PPARγ) as a molecular target for the soy phytoestrogen
genistein,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 278, no. 2, pp.
962–967, 2003.
[75] M. Mueller, S. Hobiger, and A. Jungbauer, “Red clover extract:
a source for substances that activate peroxisome proliferator-
activated receptor α and ameliorate the cytokine secre-
tion proﬁle of lipopolysaccharide-stimulated macrophages,”
Menopause, vol. 17, no. 2, pp. 379–387, 2010.
[76] L. M. Alleva, C. Cai, and I. A. Clark, “Using complementary
and alternative medicines to target the host response during
severeinﬂuenza,”Evidence-BasedComplementaryandAlterna-
tive Medicine, vol. 7, no. 4, pp. 501–510, 2010.
[77] S. L. Valles, P. Dolz-Gaiton, J. Gambini et al., “Estradiol or
genistein prevent Alzheimer’s disease-associated inﬂamma-
tioncorrelatingwithanincreasePPARγ expressionincultured
astrocytes,” Brain Research, vol. 1312, no. C, pp. 138–144,
2010.
[ 7 8 ]V .S .C a r r a r a ,A .A .A m a t o ,F .A .R .N e v e se ta l . ,“ E ﬀects
of a methanolic fraction of soybean seeds on the transcrip-
tional activity of peroxisome proliferator-activated receptors
(PPAR),” Brazilian Journal of Medical and Biological Research,
vol. 42, no. 6, pp. 545–550, 2009.
[79] A. Bitto, D. Altavilla, A. Bonaiuto et al., “Eﬀects of aglycone
Genistein in a rat experimental model of postmenopausal
metabolic syndrome,” Journal of Endocrinology, vol. 200, no.
3, pp. 367–376, 2009.
[80] Z. C. Dang, “Dose-dependent eﬀects of soy phyto-oestrogen
genistein on adipocytes: mechanisms of action: other review,”
Obesity Reviews, vol. 10, no. 3, pp. 342–349, 2009.
[81] S. Kim, H. J. Shin, S. Y. Kim et al., “Genistein enhances
expression of genes involved in fatty acid catabolism through
activation of PPARα,” Molecular and Cellular Endocrinology,
vol. 220, no. 1-2, pp. 51–58, 2004.
[ 8 2 ] D .Y .K w o n ,J .S .J a n g ,J .E .L e e ,Y .S .K i m ,D .H .
Shin, and S. Park, “The isoﬂavonoid aglycone-rich frac-
tions of Chungkookjang, fermented unsalted soybeans,
enhance insulin signaling and peroxisome proliferator-
activated receptor-γ activity in vitro,” BioFactors, vol. 26, no.
4, pp. 245–258, 2006.
[83] L. Noriega-L´ opez, A. R. Tovar, M. Gonzalez-Granillo et al.,
“Pancreatic insulin secretion in rats fed a soy protein high
fat diet depends on the interaction between the amino acid
pattern and isoﬂavones,” Journal of Biological Chemistry,v o l .
282, no. 28, pp. 20657–20666, 2007.
[84] M. J. Ronis, Y. Chen, J. Badeaux, and T. M. Badger, “Dietary
soy protein isolate attenuates metabolic syndrome inrats via10 PPAR Research
eﬀects on PPAR, LXR, and SREBP signaling,” Journal of
Nutrition, vol. 139, no. 8, pp. 1431–1438, 2009.
[ 8 5 ]P .S h e n ,M .H .L i u ,T .Y .N g ,Y .H .C h a n ,a n dE .L .
Yong, “Diﬀerential eﬀects of isoﬂavones, from Astragalus
Membranaceus and Pueraria Thomsonii, on the activation
of PPARα,P P A R γ,a n da d i p o c y t ed i ﬀerentiation in vitro,”
Journal of Nutrition, vol. 136, no. 4, pp. 899–905, 2006.
[ 8 6 ]J .D .W a g n e r ,L .Z h a n g ,M .K .S h a d o a ne ta l . ,“ E ﬀects of soy
protein and isoﬂavones on insulin resistance and adiponectin
in male monkeys,” Metabolism, vol. 57, no. 1, pp. S24–S31,
2008.
[87] Y. Takahashi and T. Ide, “Eﬀects of soy protein and
isoﬂavone on hepatic fatty acid synthesis and oxidation and
mRNA expression of uncoupling proteins and peroxisome
proliferator-activated receptor γ in adipose tissues of rats,”
Journal of Nutritional Biochemistry, vol. 19, no. 10, pp. 682–
693, 2008.